Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
about
Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulantsIs it reasonable to use a lower DOACs dose in some patients with VTE? Yes.Current challenges and future prospects in oral anticoagulant therapy.Stopping anticoagulation in a woman with unprovoked venous thromboembolism.Highlights from ACC.17 scientific sessions.Use of direct oral anticoagulants in patients on immunomodulatory agents.External validation of the DASH prediction rule: a retrospective cohort study.Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.Deciphering Conformational Changes Associated with the Maturation of Thrombin Anion Binding Exosite I.A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept.Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors.Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report.[Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].The year in cardiology 2017: prevention.A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism.Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study.Latest Innovations in the Treatment of Venous Disease.New Trends in Anticoagulation Therapy.Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency.Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature.Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic eventsPulmonary Embolism: Contemporary Medical Management and Future PerspectivesAdvances in Stroke PreventionCardioembolic stroke: everything has changedThe Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated ThrombosisWho should get long-term anticoagulant therapy for venous thromboembolism and with what?
P2860
Q33851708-1C1EAE09-FFCB-47A8-B83B-8F65CFC3C296Q36413874-B6880E14-DDBA-4C9A-B1EE-CD6B752D02F7Q38675822-979B2BB2-0A16-4A8B-A22D-BBD0224F6A80Q40056925-537B4ABF-D402-4722-A29E-CAA39DF083D8Q42205743-29C2311C-4D16-41FB-84F8-CF8DA1F508DDQ45065598-46281C67-48F1-42B7-BFCF-78B8B7D5016DQ45870309-E8F3E830-F61D-494E-BA9A-A4561D6E7E8FQ47271377-2E6C595F-240A-4291-9B19-E3A33E2B9F12Q47304199-EB245D8C-5D53-4019-A90F-629587DDCEE6Q47431685-E884AC11-FE38-41CB-9583-BA59E48B4AC5Q47779977-318E1C38-7060-4A89-9D6D-EBCAF78B919EQ47789803-79469F5A-ACAE-4C83-BD5B-C7444D1DC81AQ47959251-CF4A7F8C-14A3-42E6-95B8-18A8755E68DFQ49713074-924FB802-5A75-4C46-B864-7E2841761390Q49788980-6423AF65-24AD-4C4C-AF11-86DDEF29DB0FQ50193445-4A933AC7-4421-493D-AA2D-602DA7A4A774Q50531960-D7B44EFB-8576-455F-AEB6-BD0353DB7716Q51737332-4F68034B-20AA-449E-BCD4-793FFC9E20F3Q52594205-A780D37B-27A4-4BED-A5E5-C1E1202CA9B2Q52675244-06ACCDD2-99D1-47B7-9849-FE5672A0319CQ55199012-0FDC5167-4747-469A-80E4-1CBE50258B73Q55371591-1644C96A-3120-4BCF-83B4-C9CDDDE08F40Q55419410-81DC71D2-C856-4A8D-B7B2-36F72D0114B1Q55510457-07222472-48E7-4321-8336-81D89024D099Q58120501-30731D36-65F7-4448-8C56-F20114B62F7BQ58551043-D854AD77-B2A4-4DE4-B9D1-85AFEDB12B5DQ58695665-951FC658-0089-4781-AC5D-2DDF05A4AFDDQ58769055-B55BE917-730D-488A-BBCE-D71BE8FF2E9AQ58776758-04F9B81B-6A0C-475F-88A7-DA44BB89196EQ59133386-FB0E9991-FA7D-44EE-8C8B-C433CADFAE5F
P2860
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
@en
type
label
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
@en
altLabel
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
@en
prefLabel
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
@en
P2093
P356
P1476
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
@en
P2093
Ajay K Kakkar
Akos F Pap
Alexander T Cohen
Anthonie W A Lensing
Bonno van Bellen
Bruce L Davidson
EINSTEIN CHOICE Investigators
Gerlind Holberg
Henri Bounameaux
Hervé Decousus
P304
P356
10.1056/NEJMOA1700518
P407
P577
2017-03-18T00:00:00Z